Literature DB >> 9308950

Proton therapy for pediatric cranial tumors: preliminary report on treatment and disease-related morbidities.

B McAllister1, J O Archambeau, M C Nguyen, J D Slater, L Loredo, R Schulte, O Alvarez, A A Bedros, T Kaleita, M Moyers, D Miller, J M Slater.   

Abstract

PURPOSE: Accelerated protons were used in an attempt to limit treatment-related morbidity in children with tumors in or near the developing brain, by reducing the integral dose to adjacent normal tissues. METHODS AND MATERIALS: Children treated with protons at Loma Linda University Medical Center between August 1991 and December 1994 were analyzed retrospectively. Twenty-eight children, aged 1 to 18 years, were identified as at risk for brain injury from treatment. Medical records, physical examinations, and correspondence with patients, their parents, and referring physicians were analyzed. The investigators tabulated post-treatment changes in pre-treatment signs and symptoms and made judgments as to whether improvement, no change, or worsening related to disease or treatment had supervened. Magnetic resonance images were correlated with clinical findings and radiographic impressions were tabulated.
RESULTS: Follow-up ranged from 7 to 49 months (median 25 months). Four instances of treatment-related morbidity were identified. Forty-one instances of site-specific, disease-related morbidity were identified: 15 improved or resolved and 26 remained unchanged after treatment. Four patients had radiographic evidence of local failure. Three of these patients, including two with high-grade glioma, have died.
CONCLUSION: Early treatment-related morbidity associated with proton therapy is low. Tumor progression remains a problem when treating certain histologies such as high-grade glioma. Escalating the dose delivered to target volumes may benefit children with tumors associated with poor rates of local control. Long-term follow-up, including neurocognitive testing, is in progress to assess integral-dose effects on cognitive, behavioral and developmental outcomes in children with cranial tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9308950     DOI: 10.1016/s0360-3016(97)00079-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

Review 1.  Treatment of radiation-induced cognitive decline.

Authors:  Albert Attia; Brandi R Page; Glenn J Lesser; Michael Chan
Journal:  Curr Treat Options Oncol       Date:  2014-12

2.  Proton beam therapy (PT) in the management of CNS tumors in childhood.

Authors:  J L Habrand; H Mammar; R Ferrand; D Pontvert; P Y Bondiau; C Kalifa; J M Zucker
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

3.  Proton radiation therapy for pediatric malignancies: status report.

Authors:  E B Hug; J D Slater
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

Review 4.  Does Proton Therapy Have a Future in CNS Tumors?

Authors:  Stephanie E Combs
Journal:  Curr Treat Options Neurol       Date:  2017-03       Impact factor: 3.598

5.  Protons for pediatric ependymoma: Where are we now?

Authors:  Bernadine R Donahue; Shannon MacDonald
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029

6.  The risk of developing a second cancer after receiving craniospinal proton irradiation.

Authors:  Wayne D Newhauser; Jonas D Fontenot; Anita Mahajan; David Kornguth; Marilyn Stovall; Yuanshui Zheng; Phillip J Taddei; Dragan Mirkovic; Radhe Mohan; James D Cox; Shiao Woo
Journal:  Phys Med Biol       Date:  2009-03-20       Impact factor: 3.609

7.  Charged Particle Therapy with Mini-Segmented Beams.

Authors:  F Avraham Dilmanian; John G Eley; Adam Rusek; Sunil Krishnan
Journal:  Front Oncol       Date:  2015-12-01       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.